No abstract

No abstract

No abstract

A novel nanocomposite ] was constructed by combining ferrocene (Fc) with the porous structural metal−organic framework ]. The proposed composite material could simultaneously and efficiently remove hexavalent chromium [Cr(VI)] and imidacloprid and reduced strongly noxious Cr(VI) to weakly noxious trivalent chromium [Cr(III)]. The removal efficiencies of the composite material for Cr(VI) and imidacloprid could reach 95% after 15 h. The adsorption process was determined by kinetics, isotherms, and thermodynamics. The results demonstrated that the adsorption kinetics of Cr(VI) followed the pseudosecond-order model mainly by chemisorption; meanwhile, the adsorption of imidacloprid by the material conformed to the pseudo-first-order kinetics, which indicated that physical adsorption was the main process. Additionally, the intraparticle diffusion model revealed that the uptake of imidacloprid and Cr(VI) occurred via intraparticle diffusion at the composite material. The adsorption procedure for Cr(VI) was fitted to the Langmuir model (R 2 = 0.995) via monolayer adsorption, and that for imidacloprid was fitted to the Freundlich model (R 2 = 0.995) due to multilayer or heterogeneous adsorption. The thermodynamic research confirmed that the adsorption procedure was exothermic and spontaneous. Infrared spectroscopy, X-ray photoelectron spectra, and the pH effect implied that intermolecular hydrogen bonding and electrostatic interaction played a crucial role during the removal process. Fc-MIL-100(Fe) also exhibited long-term stability and satisfactory regeneration and reusability. Therefore, this method may enhance an environmentally friendly and prospective approach for concurrently removing imidacloprid and Cr(VI) from wastewater.

IntroductionPrevious studies have shown that patients with type 2 diabetes mellitus have an increased risk of cancer. The use of antidiabetic medication (ADM) may play an important role in the cancer development. The relationship between oral ADM and cancer incidence has not been investigated in type 2 diabetes mellitus patients in mainland China yet.MethodsA community-based diabetes cohort was extracted from the Shanghai Community Diabetes Management System database, which is a patient registry from general practices. The cohort included 2353 newly onset type 2 diabetes mellitus patients from 2006 to 2010 aged 35 years or more. Patients were grouped into nonusers of antidiabetic medication (n = 722), metformin monotherapy (n = 374), sulfonylurea monotherapy (n = 653), metformin and sulfonylurea combination therapy (n = 302), and other medication therapies (n = 302) on the basis of initial treatment type at registry entry. Cancer incidence was identified from the Shanghai Cancer Registry Organization. Comparisons between monotherapy and nonuser of medication were conducted using Cox proportional hazards models.ResultsA total of 94 cancer cases were identified during 5 years median follow-up. Compared with nonusers, sulfonylurea monotherapy was associated with significantly lower risk of cancer [adjusted HR = 0.50 (95% CI 0.29–0.85)] whereas risk was 49% lower with metformin monotherapy [adjusted HR = 0.51 (95% CI 0.27–0.99)].ConclusionThe real-world evidence suggested that the use of metformin or sulfonylurea was associated with lower risk of cancer incidence in a cohort of newly onset type 2 diabetes mellitus patients.